Fig 1: T-Cell Differentiation and Polarization in Atherosclerotic Vein Grafts After Treatment With Agonistic or Antagonistic CD137 TreatmentExperimental set-up: high-fat/cholesterol-fed ApoE3∗Leiden mice were injected either isotype (n = 6), agonistic CD137 antibodies (aCD137, agonistic treatment) (n = 4) or CD137L blocking antibodies (aCD137L, antagonistic treatment) (n = 4), and at t = 28d, vein grafts were harvested and processed for flow cytometric analysis (A). Flow cytometric analysis assessing CD8+ T-cell differentiation (B), (co-)expression of CD431B11 KLRG1 (C), CD25 (D), IFN-γ (E), IL-4 (F) and IL-17A (G) on CD8+ T-cells. Additionally, CD4+ T-cell differentiation (H) and (co-)expression of CD431B11 KLRG1 (I), CD25 (J), IFN-γ (K), IL-4 (L) and IL-17A (M) on CD4+ T-cells were analyzed after isotype or (ant)agonistic CD137 treatment. Data is represented as mean ± SD and statistically tested by 1-way analysis of variance with Dunnett post hoc test, ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001. VG = vein graft.
Fig 2: In vivo targeting of CD137: Agonistic Treatment Improves, Whereas Antagonistic Treatment Negatively Affects Vascular RemodelingExperimental set-up: high-fat/cholesterol-fed ApoE3∗Leiden mice were injected either isotype (n = 8), agonistic CD137 antibodies (aCD137, agonistic treatment) (n = 9) or CD137L blocking antibodies (aCD137L, antagonistic treatment) (n = 7). Treatment was started at t = 1d: aCD137 was administered once, while isotype and aCD137L were administered twice per week until sacrifice (A). Quantification of lumen area (B), vessel wall area (C), and total vessel area (D) of atherosclerotic vein grafts using ultra-high frequency ultrasound. Representative images of Movat Pentachrome-stained atherosclerotic vein graft lesions from mice treated with isotype, aCD137, and aCD137L (E). Quantification of histology: lumen (F), vessel wall (G), total vessel (lumen + lesion) (H), intima (I), and media area (J) in mm2, Intima/media ratio (K). Representative images and quantification of MAC3 (L), ACTA2 (M), and collagen staining (N) (normalized to total vein graft area). Data are presented as mean ± SEM and were tested using 2-way repeated measures analysis of variance or mixed-effects analysis (B-D) with repeated measures and Dunnett post hoc test. Data are presented as mean ± SD and were tested using 1-way analysis of variance or Kruskal-Wallis with Dunnett or Dunn post hoc test, respectively (F-N). ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001.
Supplier Page from BioLegend for Recombinant Human TNFSF9 (4-1BBL) (carrier-free)